These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 36200866)

  • 1. Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials.
    Bogers JPAM; Hambarian G; Walburgh Schmidt N; Vermeulen JM; de Haan L
    Schizophr Bull; 2023 Jan; 49(1):11-23. PubMed ID: 36200866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis.
    Ostuzzi G; Vita G; Bertolini F; Tedeschi F; De Luca B; Gastaldon C; Nosé M; Papola D; Purgato M; Del Giovane C; Correll CU; Barbui C
    Lancet Psychiatry; 2022 Aug; 9(8):614-624. PubMed ID: 35753323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.
    Højlund M; Kemp AF; Haddad PM; Neill JC; Correll CU
    Lancet Psychiatry; 2021 Jun; 8(6):471-486. PubMed ID: 34023019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
    Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
    Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.
    Tani H; Takasu S; Uchida H; Suzuki T; Mimura M; Takeuchi H
    Neuropsychopharmacology; 2020 Apr; 45(5):887-901. PubMed ID: 31770770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis.
    Kishi T; Ikuta T; Matsui Y; Inada K; Matsuda Y; Mishima K; Iwata N
    Psychol Med; 2019 Apr; 49(5):772-779. PubMed ID: 29909790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haloperidol versus placebo for schizophrenia.
    Adams CE; Bergman H; Irving CB; Lawrie S
    Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD003082. PubMed ID: 24242360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic Medication Continuation vs Taper and Discontinuation in Patients With Schizophrenia and Other Nonaffective Psychotic Disorders.
    Andrade C
    J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38767930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.
    Begemann MJH; Thompson IA; Veling W; Gangadin SS; Geraets CNW; van 't Hag E; Müller-Kuperus SJ; Oomen PP; Voppel AE; van der Gaag M; Kikkert MJ; Van Os J; Smit HFE; Knegtering RH; Wiersma S; Stouten LH; Gijsman HJ; Wunderink L; Staring ABP; Veerman SRT; Mahabir AGS; Kurkamp J; Pijnenborg GHM; Veen ND; Marcelis M; Grootens KP; Faber G; van Beveren NJ; Been A; van den Brink T; Bak M; van Amelsvoort TAMJ; Ruissen A; Blanke C; Groen K; de Haan L; Sommer IEC
    Trials; 2020 Feb; 21(1):147. PubMed ID: 32033579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
    Kishimoto T; Hagi K; Kurokawa S; Kane JM; Correll CU
    Lancet Psychiatry; 2021 May; 8(5):387-404. PubMed ID: 33862018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haloperidol versus placebo for schizophrenia.
    Joy CB; Adams CE; Lawrie SM
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003082. PubMed ID: 17054159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial.
    Moncrieff J; Crellin N; Stansfeld J; Cooper R; Marston L; Freemantle N; Lewis G; Hunter R; Johnson S; Barnes T; Morant N; Pinfold V; Smith R; Kent L; Darton K; Long M; Horowitz M; Horne R; Vickerstaff V; Jha M; Priebe S
    Lancet Psychiatry; 2023 Nov; 10(11):848-859. PubMed ID: 37778356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.
    Bergman H; Rathbone J; Agarwal V; Soares-Weiser K
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD000459. PubMed ID: 29409162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Slow and Steady Win the Race? Rates of Antipsychotic Discontinuation, Antipsychotic Dose, and Risk of Psychotic Relapse.
    McCutcheon RA; Taylor D; Rubio J; Nour J; Pillinger T; Murray RM; Jauhar S
    Schizophr Bull; 2024 Apr; 50(3):513-520. PubMed ID: 37797288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting psychotic relapse following randomised discontinuation of paliperidone in individuals with schizophrenia or schizoaffective disorder: an individual participant data analysis.
    Brandt L; Ritter K; Schneider-Thoma J; Siafis S; Montag C; Ayrilmaz H; Bermpohl F; Hasan A; Heinz A; Leucht S; Gutwinski S; Stuke H
    Lancet Psychiatry; 2023 Mar; 10(3):184-196. PubMed ID: 36804071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis.
    Brandt L; Schneider-Thoma J; Siafis S; Efthimiou O; Bermpohl F; Loncar L; Neumann K; Hasan A; Heinz A; Leucht S; Gutwinski S
    Lancet Psychiatry; 2022 Mar; 9(3):232-242. PubMed ID: 35183280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.